Lacosamide

Lacosamide, the active ingredient in Lacosamide, is an Anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for specific seizure types in epilepsy.

Partial‑onset seizures: reduces the frequency of focal seizures when used as monotherapy or adjunctive therapy. Primary generalized tonic‑clonic seizures: used as adjunctive therapy to help control seizure episodes in patients with this seizure type.

Lacosamide may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Suicidal ideation: thoughts of self‑harm or suicide. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic injury: signs of liver dysfunction. - Anaphylaxis: severe allergic reaction with breathing difficulty. - Cardiac conduction abnormalities: including atrioventricular block.

When prescribing Lacosamide, clinicians should consider several safety aspects.

Renal impairment: dose may need adjustment and renal function monitoring. Hepatic impairment: monitor liver enzymes and consider dose modification. Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes. Concomitant antiepileptics: assess for additive CNS effects and adjust doses. Pregnancy and breastfeeding: risk unknown, use only if benefits outweigh risks. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lacosamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide levels. - Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): increase risk of cardiac effects. - Drugs that prolong PR interval (e.g., diltiazem): may exacerbate conduction delays.

Moderate Interactions (Monitor Closely): - Oral contraceptives: efficacy may be decreased, consider alternative methods. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - CNS depressants (e.g., alcohol, benzodiazepines): may enhance sedation. - Antihypertensives: monitor blood pressure for additive effects. - Other antiepileptics: dose adjustments may be required based on therapeutic response.